Breckenridge Pharmaceutical announced the nationwide recall on November 16. Its instructions are to stop taking capsules from the recalled lot, contact a physician or other healthcare provider for medical advice and replacement instructions, and return the unused supply to the pharmacy that dispensed it.

Daylight Post found that the matching drug label explains why replacement advice is a central safety step. It warns that suddenly ending propranolol treatment has been followed by worsening angina and, in some cases, heart attacks. Angina is chest pain caused by too little blood reaching the heart muscle.

The recall addresses a potentially unsafe batch. The label addresses the risks of interrupting treatment. Read together, they show why patients need medical help with what comes next as well as a way to return the affected capsules.

Which propranolol is recalled?

The medicine is an extended-release capsule: it releases the drug gradually. The notice concerns one lot, meaning one identified production batch. The details are:

Check the affected product and batch
DetailRecalled product
MedicinePropranolol hydrochloride extended-release capsules
Strength60 mg
DistributorBreckenridge Pharmaceutical
Original bottle100 capsules
Product code, called NDC51991-817-01
Lot numberPK25110035
ExpiryMay 2029

A medicine name alone does not identify the affected supply. The Food and Drug Administration, the US medicines regulator, tells patients to compare the lot number with the recall notice. If the pharmacy’s label does not show it, ask the dispensing pharmacy to check the supply you received.

Why the replacement needs medical direction

Propranolol is a beta blocker, a medicine that reduces the effects of signals that make the heart work harder. The extended-release capsules are prescribed for conditions including high blood pressure, angina and prevention of migraines. A person taking them does not necessarily have heart disease.

The label’s warning concerns interruption of treatment, particularly in people with coronary artery disease, where narrowed arteries reduce blood flow to the heart. It cautions patients against ending treatment without their physician’s advice. It also notes that this heart disease may not always have been recognized.

That warning does not cancel the instruction to stop using the recalled capsules. It makes prompt advice about replacement important. A patient should not have to work out a new dose or a different medicine from a general recall headline.

The formulation also matters. The label says the slow-release capsules are not a simple milligram-for-milligram substitute for ordinary propranolol tablets, which release the medicine more quickly. A matching number on another packet does not establish that it can be taken in the same way.

What is known about the contamination

The company says the affected lot used material shared with a different lot in which metal contamination was found. That other lot was not released. Possible metal pieces could cut tissue in the mouth or digestive tract. The company said it knew of no health problems assessed as related to this recall.

The safety response goes beyond returning stock

FDA guidance says patients should follow the recalling company’s directions and speak to a doctor or pharmacist about questions concerning their medicine. The agency oversees companies’ recall plans and checks whether customers were properly notified and the defective product removed.

The immediate task for an affected patient is to act on the lot-specific recall and obtain professional instructions for continuing their care. Returning the product and arranging appropriate treatment are parts of the same safety response.